140 related articles for article (PubMed ID: 9792131)
1. Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results.
Sodee DB; Ellis RJ; Samuels MA; Spirnak JP; Poole WF; Riester C; Martanovic DM; Stonecipher R; Bellon EM
Prostate; 1998 Nov; 37(3):140-8. PubMed ID: 9792131
[TBL] [Abstract][Full Text] [Related]
2. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients.
Elgamal AA; Troychak MJ; Murphy GP
Prostate; 1998 Dec; 37(4):261-9. PubMed ID: 9831223
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers.
Sodee DB; Malguria N; Faulhaber P; Resnick MI; Albert J; Bakale G
Urology; 2000 Dec; 56(6):988-93. PubMed ID: 11113745
[TBL] [Abstract][Full Text] [Related]
5. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy.
Fang DX; Stock RG; Stone NN; Krynyckyi BR; Kim CK; Machac J
Tech Urol; 2000 Jun; 6(2):146-50. PubMed ID: 10798816
[TBL] [Abstract][Full Text] [Related]
6. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.
Wilkinson S; Chodak G
J Urol; 2004 Jul; 172(1):133-6. PubMed ID: 15201753
[TBL] [Abstract][Full Text] [Related]
7. Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy.
Murphy GP; Elgamal AA; Troychak MJ; Kenny GM
Prostate; 2000 Mar; 42(4):315-7. PubMed ID: 10679761
[TBL] [Abstract][Full Text] [Related]
8. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy.
Proaño JM; Sodee DB; Resnick MI; Einstein DB
J Urol; 2006 May; 175(5):1668-72. PubMed ID: 16600726
[TBL] [Abstract][Full Text] [Related]
9. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer.
Ellis RJ; Kaminsky DA; Zhou EH; Fu P; Chen WD; Brelin A; Faulhaber PF; Bodner D
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):29-34. PubMed ID: 20961696
[TBL] [Abstract][Full Text] [Related]
10. Progress in SPECT/CT imaging of prostate cancer.
Seo Y; Franc BL; Hawkins RA; Wong KH; Hasegawa BH
Technol Cancer Res Treat; 2006 Aug; 5(4):329-36. PubMed ID: 16866563
[TBL] [Abstract][Full Text] [Related]
11. Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer.
Sodee DB; Conant R; Chalfant M; Miron S; Klein E; Bahnson R; Spirnak JP; Carlin B; Bellon EM; Rogers B
Clin Nucl Med; 1996 Oct; 21(10):759-67. PubMed ID: 8896922
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
[TBL] [Abstract][Full Text] [Related]
13. Role of ProstaScint for brachytherapy in localized prostate adenocarcinoma.
Ellis RJ; Kim E; Foor R
Expert Rev Mol Diagn; 2004 Jul; 4(4):435-41. PubMed ID: 15225091
[TBL] [Abstract][Full Text] [Related]
14. Detection and localization of carcinoma within the prostate using high resolution transrectal gamma imaging (TRGI) of monoclonal antibody directed at prostate specific membrane antigen (PSMA)--proof of concept and initial imaging results.
Franc BL; Cho SY; Rosenthal SA; Cui Y; Tsui B; Vandewalker KM; Holz AL; Poonamallee U; Pomper MG; James RB
Eur J Radiol; 2013 Nov; 82(11):1877-84. PubMed ID: 23993140
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation.
Ellis RJ; Kim EY; Conant R; Sodee DB; Spirnak JP; Dinchman KH; Beddar S; Wessels B; Resnick MI; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1281-6. PubMed ID: 11286835
[TBL] [Abstract][Full Text] [Related]
16. The dual-isotope ProstaScint imaging procedure: clinical experience and staging results in 145 patients.
Quintana JC; Blend MJ
Clin Nucl Med; 2000 Jan; 25(1):33-40. PubMed ID: 10634528
[TBL] [Abstract][Full Text] [Related]
17. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients.
Murphy GP; Maguire RT; Rogers B; Partin AW; Nelp WB; Troychak MJ; Ragde H; Kenny GM; Barren RJ; Bowes VA; Gregorakis AK; Holmes EH; Boynton AL
Prostate; 1997 Dec; 33(4):281-5. PubMed ID: 9397201
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint scintiscans.
Murphy GP; Snow PB; Brandt J; Elgamal A; Brawer MK
Prostate; 2000 Feb; 42(2):145-9. PubMed ID: 10617872
[TBL] [Abstract][Full Text] [Related]
19. The utility of monoclonal antibodies in the imaging of prostate cancer.
Yao D; Trabulsi EJ; Kostakoglu L; Vallabhajosula S; Joyce MA; Nanus DM; Milowsky M; Liu H; Goldsmith SJ
Semin Urol Oncol; 2002 Aug; 20(3):211-8. PubMed ID: 12215974
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease.
Ponsky LE; Cherullo EE; Starkey R; Nelson D; Neumann D; Zippe CD
Prostate Cancer Prostatic Dis; 2002; 5(2):132-5. PubMed ID: 12497003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
